|Articles|September 1, 2018
- Pharmaceutical Executive-09-01-2018
- Volume 38
- Issue 9
Pharmaceutical Executive, September 2018 Issue (PDF)
Click the title above to open the Pharmaceutical Executive September 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 8 years ago
Paul Perreault: The Global CEOalmost 8 years ago
Specialty Pharma’s Move to Mainstreamalmost 8 years ago
Specialty Product Launch Insightsalmost 8 years ago
Beyond Big Data: Meeting the Specialty Marketing Challengealmost 8 years ago
Specialty Focus: Tackling Rare Mutation in CFalmost 8 years ago
The ‘Spare-No-Expense’ Alternativealmost 8 years ago
Pharm Exec's 17th Annual Industry Auditalmost 8 years ago
Specialty Supply Chain Decisionsalmost 8 years ago
FDA Struggles to Advance Biosimilarsalmost 8 years ago
Country Report: UKAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Beyond the Megamerger: How Rumored AstraZeneca–BMS Discussions Signal a New Era of Pharmaceutical Competition
3
FDA Grants Accelerated Approval to Tudriqev in Combination with Nivoumab for Advanced Melanoma
4
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for $450 Million
5